ZHAOKE OPHTH-B (06622) surged over 8% in the afternoon session. As of press time, the stock was up 7.14% to HK$3.75, with a turnover of HK$11.603 million.

On the news front, ZHAOKE OPHTH-B released its interim results, reporting revenue of RMB 15.803 million, down 68.25% year-over-year; net loss was RMB 117 million, up 53.85% year-over-year.

Notably, in the first half of 2025, three core drug candidates of ZHAOKE OPHTH-B - Atropine Sulfate Eye Drops, Cyclosporine Ophthalmic Gel, and Bevacizumab Intravitreal Injection - have entered the New Drug Application (NDA) stage. The company expects to achieve the important goal of commercializing a cumulative total of 12 drugs by the end of 2026.

ZHAOKE OPHTH-B previously announced that the company has signed a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals for the Indonesian market regarding its core product: Atropine Sulfate Eye Drops (NVK002) for slowing myopia progression in children and adolescents.

Under the terms of the agreement, ZHAOKE OPHTH-B grants PT Ferron exclusive rights to import, promote, distribute, market and sell the product in Indonesia. ZHAOKE OPHTH-B will receive an upfront payment and may receive additional milestone payments based on certain achievements.